Diabetes mellitus is a severe, chronic disease that affects over 420 million people worldwide. If left untreated, diabetes can lead to severe complications and death. The onset of complications can be delayed or even prevented when the disease is diagnosed early, but it is estimated that nearly 40% of all persons with diabetes are undiagnosed. Screening in communities with limited access to healthcare can significantly reduce the number of undiagnosed cases of diabetes. The blood concentration of 1,5-anhydroglucitol (AHG), a naturally-occurring six-carbon monosaccharide similar in structure to glucose, falls during periods of hyperglycemia as glucose outcompetes AHG for kidney reuptake. Blood AHG measurement is an FDA-cleared method of monitoring glycemic control, and salivary AHG has been suggested to be useful for diabetes screening. However, previous efforts to measure AHG in saliva have been unsuccessful. We have developed a chemiluminescence assay to quantify AHG in saliva and demonstrated that the assay could distinguish between healthy and treated-diabetic individuals (N=265; p &lt; 0.001, ROC AUC 0.82). These results suggest that, with further validation, this approach may serve as the basis of a non-invasive tool to screen for diabetes.

Detection of salivary 1,5-anhydroglucitol for convenient, non-invasive diabetes mellitus screening

ACS Spring Meeting 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.